Schizophrenia

How physicians in a shrinking field have taken on a greater burden of leadership roles in patient care.

How does psychiatry access differ among patients, and how should it become individualized?

The new transdermal patch offers a new delivery option for a well-established schizophrenia treatment.

In a comprehensive new study, investigators discover unique patterns in the brains of both family members and patients with psychotic disorders, including bipolar disorder and schizophrenia.

This week's #DocTalk tweet chat generated discussion on the means by which healthcare professionals can influence mental health policies and understanding.

A cohort study analysis shows clozapine is effective in treating schizophrenia, despite adverse effects.

The meta-analysis was comprised of 402 individual studies in which the primary therapy was 1 of 32 antipsychotics.

Allergan announced the FDA approved a New Drug Application for Vraylar for the treatment of depressive episodes associated with bipolar depression.

Investigators presented 2 pooled analyses at APA 2019 that explored the safety profile and efficacy of 42mg lumateperone in patients with schizophrenia

Investigators presented the results of a 4-week trial examining the efficacy of SEP-363856 at APA 2019 in San Francisco, CA.

Godfrey Pearlson, MD, founding director of the division of psychiatry neuroimaging at Johns Hopkins University, discusses the possibility of using neuroimaging to diagnose psychiatric disorders.

Godfrey Pearlson sat down at APA 2019 to discuss his opinion on what the most significant recent advances in neuropsychiatry have been and how they have impacted practice.

Pear Therapeutics and Novartis presented findings from their study exploring the use of digital therapies in addition to traditional treatment in patients with schizophrenia.

The investigative drug SEP-363856 has been evidenced in a phase 2 trial to reduced hospitalized patient symptoms and severity.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.

Both long-acting injectable treatments produced statistically significant and clinically meaningful improvements.

The antipsyhoctic could receive a new indication in 2019, and though the field of bipolar disorder care is far from perfect, it should improve with this addition.

A retrospective study showed which patients with substance use disorder may have less successful antiepileptic drug treatment.

A more multidisciplinary, collaborative care effort for these patients can result in more active monitoring and productive clinical care.